Podcasts about immunotherapy forum video

Immunotherapy Forum Video #31: "You know the world is changing when you have to change the rules..." Following presentations on endpoints and biomarkers in cancer immunotherapy, the doctors take questions from the audience.

Immunotherapy Forum Video #31: "You know the world is changing when you have to change the rules..." Following presentations on endpoints and biomarkers in cancer immunotherapy, the doctors take questions from the audience.

Immunotherapy Forum Video #31: "You know the world is changing when you have to change the rules..." Following presentations on endpoints and biomarkers in cancer immunotherapy, the doctors take questions from the audience.

Immunotherapy Forum Video #30: Immunotherapy for cancer has rewritten the rules for what we consider a successful response to treatment. Some tumors grow before they regress. Dr. Jedd Wolchok discusses why a new measurement criteria was developed.

Immunotherapy Forum Video #30: Immunotherapy for cancer has rewritten the rules for what we consider a successful response to treatment. Some tumors grow before they regress. Dr. Jedd Wolchok discusses why a new measurement criteria was developed.

Immunotherapy Forum Video #30: Immunotherapy for cancer has rewritten the rules for what we consider a successful response to treatment. Some tumors grow before they regress. Dr. Jedd Wolchok discusses why a new measurement criteria was developed.

Immunotherapy Forum Video #29: In part 2 of 2, Dr. Jason Luke discusses treating cancer with immunotherapy and another drug, such chemotherapy or targeted therapies, as well as what we know about biomarkers that predict if an immunotherapeutic will work.

Immunotherapy Forum Video #29: In part 2 of 2, Dr. Jason Luke discusses treating cancer with immunotherapy and another drug, such chemotherapy or targeted therapies, as well as what we know about biomarkers that predict if an immunotherapeutic will work.

Immunotherapy Forum Video #29: In part 2 of 2, Dr. Jason Luke discusses treating cancer with immunotherapy and another drug, such chemotherapy or targeted therapies, as well as what we know about biomarkers that predict if an immunotherapeutic will work.

Immunotherapy Forum Video #28: Doctors are still weighing the pros and cons of giving a cancer patient immunotherapy before or after resection surgery. In part 1 of 2 videos, Dr. Jason Luke details those risks and benefits.

Immunotherapy Forum Video #28: Doctors are still weighing the pros and cons of giving a cancer patient immunotherapy before or after resection surgery. In part 1 of 2 videos, Dr. Jason Luke details those risks and benefits.

Immunotherapy Forum Video #28: Doctors are still weighing the pros and cons of giving a cancer patient immunotherapy before or after resection surgery. In part 1 of 2 videos, Dr. Jason Luke details those risks and benefits.

Immunotherapy Forum Video #27: Immunotherapies work well in some, but not in others. Who benefits, and why? Dr. Sumanta (Monty) Pal explains what doctors are learning.

Immunotherapy Forum Video #27: Immunotherapies work well in some, but not in others. Who benefits, and why? Dr. Sumanta (Monty) Pal explains what doctors are learning.

Immunotherapy Forum Video #27: Immunotherapies work well in some, but not in others. Who benefits, and why? Dr. Sumanta (Monty) Pal explains what doctors are learning.

Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy for lung cancer. Moderated by Dr. Jack West.

Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy for lung cancer. Moderated by Dr. Jack West.

Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy for lung cancer. Moderated by Dr. Jack West.

Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr. Matthew Hellmann discusses currently enrolling clinical trials for lung cancer patients that study combination therapies (meaning an immunotherapy drug plus another drug is given).

Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr. Matthew Hellmann discusses currently enrolling clinical trials for lung cancer patients that study combination therapies (meaning an immunotherapy drug plus another drug is given).

Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr. Matthew Hellmann discusses currently enrolling clinical trials for lung cancer patients that study combination therapies (meaning an immunotherapy drug plus another drug is given).

Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials currently available to early and late stage lung cancer patients that study single agent immunotherapies (i.e. only one treatment is given).

Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials currently available to early and late stage lung cancer patients that study single agent immunotherapies (i.e. only one treatment is given).

Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials currently available to early and late stage lung cancer patients that study single agent immunotherapies (i.e. only one treatment is given).

Immunotherapy Forum Video #23: Dr. Jared Weiss highlights what doctors know about immunotherapy treatments for lung cancer. His words: "The pace of progress that I expect over the next 3 to 5 years will shock even the most optimistic..."

Immunotherapy Forum Video #23: Dr. Jared Weiss highlights what doctors know about immunotherapy treatments for lung cancer. His words: "The pace of progress that I expect over the next 3 to 5 years will shock even the most optimistic..."

Immunotherapy Forum Video #23: Dr. Jared Weiss highlights what doctors know about immunotherapy treatments for lung cancer. His words: "The pace of progress that I expect over the next 3 to 5 years will shock even the most optimistic..."

Immunotherapy Forum Video #22: Drs. Lauren Harshman and Sumanta (Monty) Pal answer questions from the audience following their presentations on immunotherapy for kidney cancer. Moderated by Dr. Marianne Davies.

Immunotherapy Forum Video #22: Drs. Lauren Harshman and Sumanta (Monty) Pal answer questions from the audience following their presentations on immunotherapy for kidney cancer. Moderated by Dr. Marianne Davies.

Immunotherapy Forum Video #22: Drs. Lauren Harshman and Sumanta (Monty) Pal answer questions from the audience following their presentations on immunotherapy for kidney cancer. Moderated by Dr. Marianne Davies.

Immunotherapy Forum Video #21: Dr. Sumanta (Monty) Pal reviews the past, present, and future of immunotherapy for kidney cancer and expresses concern about early study results of newer treatments. 

Immunotherapy Forum Video #21: Dr. Sumanta (Monty) Pal reviews the past, present, and future of immunotherapy for kidney cancer and expresses concern about early study results of newer treatments. 

Immunotherapy Forum Video #21: Dr. Sumanta (Monty) Pal reviews the past, present, and future of immunotherapy for kidney cancer and expresses concern about early study results of newer treatments. 

Immunotherapy Forum Video #20: Dr. Lauren Harshman talks about clinical trials studying the CTLA-4 pathway, as well as vaccines. 

Immunotherapy Forum Video #20: Dr. Lauren Harshman talks about clinical trials studying the CTLA-4 pathway, as well as vaccines. 

Immunotherapy Forum Video #20: Dr. Lauren Harshman talks about clinical trials studying the CTLA-4 pathway, as well as vaccines. 

Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.

Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.

Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.

Immunotherapy Forum Video #18: Drs. Topalian and Wolchok sat for a moderated Q&A with Dr. Louise Perkins from the Melanoma Research Alliance following their presentations on immunotherapy for melanoma.

Immunotherapy Forum Video #18: Drs. Topalian and Wolchok sat for a moderated Q&A with Dr. Louise Perkins from the Melanoma Research Alliance following their presentations on immunotherapy for melanoma.

Immunotherapy Forum Video #18: Drs. Topalian and Wolchok sat for a moderated Q&A with Dr. Louise Perkins from the Melanoma Research Alliance following their presentations on immunotherapy for melanoma.

Immunotherapy Forum Video #17: In Part 2 of 2 videos on this topic, Dr. Jedd Wolchok discusses side effects related to immunotherapy, combination therapies, and information about new immunotherapies currently being studied for treating melanoma.

Immunotherapy Forum Video #17: In Part 2 of 2 videos on this topic, Dr. Jedd Wolchok discusses side effects related to immunotherapy, combination therapies, and information about new immunotherapies currently being studied for treating melanoma.

Immunotherapy Forum Video #17: In Part 2 of 2 videos on this topic, Dr. Jedd Wolchok discusses side effects related to immunotherapy, combination therapies, and information about new immunotherapies currently being studied for treating melanoma.

Immunotherapy Forum Video #16: In Part 1 of 2 videos on this topic, Dr. Jedd Wolchok provides a history of one of the first immunotherapy drugs, Yervoy (ipilumumab), and the evidence that led to its approval.

Immunotherapy Forum Video #16: In Part 1 of 2 videos on this topic, Dr. Jedd Wolchok provides a history of one of the first immunotherapy drugs, Yervoy (ipilumumab), and the evidence that led to its approval.

Immunotherapy Forum Video #16: In Part 1 of 2 videos on this topic, Dr. Jedd Wolchok provides a history of one of the first immunotherapy drugs, Yervoy (ipilumumab), and the evidence that led to its approval.

Immunotherapy Forum Video #15: In Part 2 of 2 videos on this topic, Dr. Suzanne Topalian discusses the immunotherapy drugs that are currently approved for the treatment of melanoma as well as future treatments on the horizon.

Immunotherapy Forum Video #15: In Part 2 of 2 videos on this topic, Dr. Suzanne Topalian discusses the immunotherapy drugs that are currently approved for the treatment of melanoma as well as future treatments on the horizon.

Immunotherapy Forum Video #15: In Part 2 of 2 videos on this topic, Dr. Suzanne Topalian discusses the immunotherapy drugs that are currently approved for the treatment of melanoma as well as future treatments on the horizon.

Immunotherapy Forum Video #14: In Part 1 of 2 videos on this topic, Dr. Suzanne Topalian provides a background on melanoma in the United States and how immunotherapy treatment for it has progessed over the past three decades.

Immunotherapy Forum Video #14: In Part 1 of 2 videos on this topic, Dr. Suzanne Topalian provides a background on melanoma in the United States and how immunotherapy treatment for it has progessed over the past three decades.

Immunotherapy Forum Video #14: In Part 1 of 2 videos on this topic, Dr. Suzanne Topalian provides a background on melanoma in the United States and how immunotherapy treatment for it has progessed over the past three decades.

Immunotherapy Forum Video #12: In Part 2 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.

Immunotherapy Forum Video #12: In Part 2 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.

Immunotherapy Forum Video #12: In Part 2 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.

Immunotherapy Forum Video #12: In Part 2 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.

Immunotherapy Forum Video #12: In Part 2 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.

Immunotherapy Forum Video #12: In Part 2 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.

Immunotherapy Forum Video #11: In Part 1 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.

Immunotherapy Forum Video #11: In Part 1 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.

Immunotherapy Forum Video #11: In Part 1 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.

Immunotherapy Forum Video #10: "For all of the scholarly individuals here to give you the science, I'm here to give you the proof," is how stage IV melanoma patient Rusty Cline kicks off the story of his remarkable response to immunotherapy. 

Immunotherapy Forum Video #10: "For all of the scholarly individuals here to give you the science, I'm here to give you the proof," is how stage IV melanoma patient Rusty Cline kicks off the story of his remarkable response to immunotherapy. 

Immunotherapy Forum Video #10: "For all of the scholarly individuals here to give you the science, I'm here to give you the proof," is how stage IV melanoma patient Rusty Cline kicks off the story of his remarkable response to immunotherapy. 

Immunotherapy Forum Video #9: In Part 2 of 2 videos on this topic, oncology nurse Dr. Marianne Davies discusses the side effects that cancer patients who undergo immunotherapy treatment may experience and how to minimize them.

Immunotherapy Forum Video #9: In Part 2 of 2 videos on this topic, oncology nurse Dr. Marianne Davies discusses the side effects that cancer patients who undergo immunotherapy treatment may experience and how to minimize them.

Immunotherapy Forum Video #9: In Part 2 of 2 videos on this topic, oncology nurse Dr. Marianne Davies discusses the side effects that cancer patients who undergo immunotherapy treatment may experience and how to minimize them.

Immunotherapy Forum Video #8: In Part 1 of 2 videos on this topic, oncology nurse Dr. Marianne Davies discusses the side effects that cancer patients who undergo immunotherapy treatment may experience and how to minimize them.

Immunotherapy Forum Video #8: In Part 1 of 2 videos on this topic, oncology nurse Dr. Marianne Davies discusses the side effects that cancer patients who undergo immunotherapy treatment may experience and how to minimize them.

Immunotherapy Forum Video #8: In Part 1 of 2 videos on this topic, oncology nurse Dr. Marianne Davies discusses the side effects that cancer patients who undergo immunotherapy treatment may experience and how to minimize them.

Immunotherapy Forum Video #7: Drs. Pardoll, Hellman, and Luke sat for a moderated Q&A with Dr. Jack West.

Immunotherapy Forum Video #7: Drs. Pardoll, Hellman, and Luke sat for a moderated Q&A with Dr. Jack West.

Immunotherapy Forum Video #7: Drs. Pardoll, Hellman, and Luke sat for a moderated Q&A with Dr. Jack West.

Immunotherapy Forum Video #6: In Part 2 of 2 videos on this topic, Dr. Jason Luke from the University of Chicago talks about the types of immunotherapy currently in use for melanoma, kidney cancer, and lung cancer and how they are given to patients.

Immunotherapy Forum Video #6: In Part 2 of 2 videos on this topic, Dr. Jason Luke from the University of Chicago talks about the types of immunotherapy currently in use for melanoma, kidney cancer, and lung cancer and how they are given to patients.

Immunotherapy Forum Video #6: In Part 2 of 2 videos on this topic, Dr. Jason Luke from the University of Chicago talks about the types of immunotherapy currently in use for melanoma, kidney cancer, and lung cancer and how they are given to patients.

Immunotherapy Forum Video #5: In Part 1 of 2 videos on this topic, Dr. Jason Luke from the University of Chicago talks about the types of immunotherapy currently in use for melanoma, kidney cancer, and lung cancer and how they are given to patients.

Immunotherapy Forum Video #5: In Part 1 of 2 videos on this topic, Dr. Jason Luke from the University of Chicago talks about the types of immunotherapy currently in use for melanoma, kidney cancer, and lung cancer and how they are given to patients.